XML 65 R51.htm IDEA: XBRL DOCUMENT
v3.23.2

Principal Changes in Scope of Consolidation in the Period and Amendments to Principal Agreements - Amendments to Principal Agreements (Details) - EUR (€) € in Millions |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 17, 2023 | Apr. 11, 2023 | Apr. 09, 2023 | Nov. 30, 2022 | Mar. 31, 2017 | Sep. 30, 2019 | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Other non-current liabilities |  |  |  |  |  |  | € 2,070 | € 519 | € 422
Other intangible assets excluding software |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Acquisitions and other increases |  |  |  |  |  |  | 1,757 |  |
Antibodies Collaboration Agreement | AstraZeneca |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Collaboration agreements, upfront payment |  |  |  |  | € 120 |  |  |  |
Collaboration agreements, development milestone payment |  |  |  |  |  | € 30 |  |  |
Collaboration agreements, regulatory milestone payment |  |  |  | € 25 |  |  |  |  |
Commitments related to potential milestone payments for projects under collaboration agreements |  |  |  |  |  |  | € 440 |  |
Percentage of development costs arising from commercial operations |  |  |  |  |  |  | 50.00% |  |
Antibodies Collaboration Agreement | AstraZeneca | Other intangible assets excluding software |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Acquisitions and other increases |  | € 1,632 | € 1,632 |  |  |  |  |  |
Antibodies Collaboration Agreement | AstraZeneca | Other intangible assets excluding software | Major financial liability |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Acquisitions and other increases | € 65 |  |  |  |  |  |  |  |
Antibodies Collaboration Agreement | AstraZeneca | Major territories |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  |  | 50.00% |  |
Antibodies Collaboration Agreement | AstraZeneca | Other territories |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Percentage of net sales arising from commercial operations |  |  |  |  |  |  | 25.00% |  |
Antibodies Collaboration Agreement | AstraZeneca | China |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Percentage of profits arising from commercial operations |  |  |  |  |  |  | 50.00% |  |
Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Other non-current liabilities |  |  | 1,609 |  |  |  | € 1,613 |  |
Other current liabilities |  |  | € 23 |  |  |  |  |  |
Antibodies Collaboration Agreement | Swedish Orphan Biovitrum AB | Major financial liability |  |  |  |  |  |  |  |  |
Disclosure Of Principal Agreements [Line Items] |  |  |  |  |  |  |  |  |
Increase through remeasurement of financial liability | € 50 |  |  |  |  |  |  |  |

X
- Definition The amount of additions to intangible assets other than goodwill, other than those acquired through business combinations. [Refer: Business combinations [member]; Intangible assets other than goodwill] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 38 -IssueDate 2022-03-24 -Paragraph 118 -Subparagraph e -Clause i -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_i&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_AdditionsOtherThanThroughBusinessCombinationsIntangibleAssetsOtherThanGoodwill
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_OtherCurrentLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of non-current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Non-current liabilities] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2022-03-24 -Paragraph 55 -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard -URIDate 2022-03-24 + Details
Name: | ifrs-full_OtherNoncurrentLiabilities
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaboration Agreements, Development Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsDevelopmentMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Regulatory Milestone Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsRegulatoryMilestonePayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Collaboration Agreements, Upfront Payment + References No definition available. + Details
Name: | sny_CollaborationAgreementsUpfrontPayment
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Commitments Related To Milestone Payments For Projects Under Collaboration Agreement + References No definition available. + Details
Name: | sny_CommitmentsRelatedToMilestonePaymentsForProjectsUnderCollaborationAgreement
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Principal Agreements [Line Items] + References No definition available. + Details
Name: | sny_DisclosureOfPrincipalAgreementsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Increase (Decrease) Through Remeasurement, Other Non-Current Liabilities + References No definition available. + Details
Name: | sny_IncreaseDecreaseThroughRemeasurementOtherCurrentLiabilities
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage Of Development Costs Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfDevelopmentCostsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Net Sales Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfNetSalesArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage Of Profits Arising From Commercial Operations + References No definition available. + Details
Name: | sny_PercentageOfProfitsArisingFromCommercialOperations
Namespace Prefix: | sny_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis=sny_OtherIntangibleAssetsExcludingSoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | sny_PrincipalAlliancesAxis=sny_AntibodiesCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_AstraZenecaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=sny_MajorFinancialLiabilityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_MajorTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=sny_OtherTerritoriesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_GeographicalAreasAxis=country_CN
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_CounterpartiesAxis=sny_SwedishOrphanBiovitrumABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |